Top

Published in:

01-09-2008 | Original Paper

Different Expression of Occludin and ZO-1 in Primary and Metastatic Liver Tumors

Authors: Erika Orbán, Erzsébet Szabó, Gábor Lotz, Péter Kupcsulik, Csilla Páska, Zsuzsa Schaff, András Kiss

Published in: Pathology & Oncology Research | Issue 3/2008

Abstract

Tight junction (TJ) components were found to be correlated with carcinogenesis and tumor development. TJs are composed of three main integral membrane proteins; occludin, claudins and JAMs. Alteration of the TJ protein expression may play an important role in the process of cell dissociation, which is among the first steps of tumor invasion and metastasis. Reduced expression of ZO-1 has been reported to be associated with invasion of several tumors. The aim of the present study was to detect differences between occludin and ZO-1 expression in normal liver samples, HCCs and colorectal liver metastases. Expression of occludin and ZO-1 was analysed in 25 surgically removed human hepatocellular carcinomas (HCC) and 25 human colorectal liver metastases. Gene expression levels were measured by real-time RT PCR, protein expression was determined by immunohistochemistry, comparing tumors with the surrounding nontumorous parenchyma and with seven normal liver samples. Occludin and ZO-1 mRNAs showed significant downregulation in HCCs in comparison with normal liver and were also downregulated in the metastases when compared with normal liver. Occludin and ZO-1 proteins were weakly expressed on hepatocytes in normal liver, while strong expression was found on bile canaliculi. In HCCs occludin and ZO-1 did not show immunopositivity on tumor cells, while colorectal metastatic tumors revealed high levels of these molecules. HCCs and metastases are characterized by markedly different protein expression pattern of occludin and ZO-1, which phenomenon might be attributed to the different histogenesis of these tumors.

Jiang WG (1998) Cell adhesion molecules in the formation of liver metastasis. J Hepatobiliary Pancreat Surg 5:375–382CrossRefPubMed

Kaihara T, Kusaka T, Nishi M et al. (2003) Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are closely related to liver metastasis. J Exp Clin Cancer Res 22:117–123PubMed

Sakisaka S, Kawaguchi T, Taniguchi E et al. (2001) Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 33:1460–1468CrossRefPubMed

Kojima T, Yamamoto T, Murata M et al. (2003) Regulation of the blood–biliary barrier: interaction between gap and tight junctions in hepatocytes. Med Electron Microsc 36:157–164CrossRefPubMed

Haynes MD, Martin TA, Jenkins SA et al. (2005) Tight junctions and bladder cancer (review). Int J Mol Med 16:3–9PubMed

Cereijido M, Shoshani L, Contreras RG (2000) Molecular physiology and pathophysiology of tight junctions. I. Biogenesis of tight junctions and epithelial polarity. Am J Physiol Gastrointest Liver Physiol 279:G477–482PubMed

Fanning AS, Mitic LL, Anderson JM (1999) Transmembrane proteins in the tight junction barrier. J Am Soc Nephrol 10:1337–1345PubMed

Saitou M, Furuse M, Sasaki H et al. (2000) Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 11:4131–4142PubMed

Gonzalez-Mariscal L, Betanzos A, Nava P et al. (2003) Tight junction proteins. Prog Biophys Mol Biol 81:1–44CrossRefPubMed

10.

Itoh M, Nagafuchi A, Yonemura S et al. (1993) The 220-kD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-1, a tight junction-associated protein in epithelial cells: cDNA cloning and immunoelectron microscopy. J Cell Biol 121:491–502CrossRefPubMed

11.

Itoh M, Furuse M, Morita K et al. (1999) Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J Cell Biol 147:1351–1363CrossRefPubMed

12.

Ebnet K, Schulz CU, Meyer Zu Brickwedde MK et al. (2000) Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. J Biol Chem 275:27979–27988PubMed

13.

Fanning AS, Jameson BJ, Jesaitis LA et al. (1998) The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 273:29745–29753CrossRefPubMed

14.

Wittchen ES, Haskins J, Stevenson BR (1999) Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J Biol Chem 274:35179–35185CrossRefPubMed

15.

Fanning AS, Anderson JM (1999) PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J Clin Invest 103:767–772CrossRefPubMed

16.

Lodi C, Szabo E, Holczbauer A et al. (2006) Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Pathol 19:460–469CrossRefPubMed

17.

Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36CrossRefPubMed

18.

Tan X, Tamori Y, Egami H et al. (2004) Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation. Oncol Rep 11:993–998PubMed

19.

Schneeberger EE, Lynch RD (2004) The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286:C1213–1228CrossRefPubMed

20.

Saitou M, Fujimoto K, Doi Y et al. (1998) Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions. J Cell Biol 141:397–408CrossRefPubMed

21.

Smalley KS, Brafford P, Haass NK et al. (2005) Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166:1541–1554PubMed

22.

Mauro L, Bartucci M, Morelli C et al. (2001) IGF-I receptor-induced cell–cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 276:39892–39897CrossRefPubMed

23.

Palmer HG, Gonzalez-Sancho JM, Espada J et al. (2001) Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154:369–387CrossRefPubMed

24.

Brabletz T, Jung A, Reu S et al. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 98:10356–10361CrossRefPubMed

25.

Busch C, Hanssen TA, Wagener C et al. (2002) Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol 33:290–298CrossRefPubMed

26.

Kimura Y, Shiozaki H, Hirao M et al. (1997) Expression of occludin, tight-junction-associated protein, in human digestive tract. Am J Pathol 151:45–54PubMed

27.

Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology. 46:551–60CrossRefPubMed

28.

Cheung ST, Leung KL, Ip YC et al. (2005) Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 11:551–556PubMed

29.

Ishikawa Y, Akishima-Fukasawa Y, Ito K et al. (2008) Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer 112:924–933CrossRefPubMed

30.

Kominsky SL, Tyler B, Sosnowski J et al. (2007) Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 67:7977–7982CrossRefPubMed

31.

Sawada N, Murata M, Kikuchi K et al. (2003) Tight junctions and human diseases. Med Electron Microsc 36:147–156CrossRefPubMed

Title: Different Expression of Occludin and ZO-1 in Primary and Metastatic Liver Tumors
Authors: Erika Orbán
Erzsébet Szabó
Gábor Lotz
Péter Kupcsulik
Csilla Páska
Zsuzsa Schaff
András Kiss
Publication date: 01-09-2008
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-008-9031-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Bcl-2 Antisense Oligonucleotide Inhibits the Proliferation of Childhood Leukemia/lymphoma Cells of the B-cell Lineage

Extracellular ATP and Cancer—An Overview with Special Reference to P2 Purinergic Receptors

Prolonged Survival Using Anti-CD20 Combined Chemotherapy in Primary Prostatic Intravascular Large B-cell Lymphoma

Systemic Dissemination in Cancer of Unknown Primary is Independent of Mutational Inactivation of the KiSS-1 Metastasis-suppressor Gene

K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma

Focal Lymphoid Hyperplasia of the Terminal Ileum Presenting Mantle Zone Hyperplasia with Clear Cytoplasm. A Report of Three Cases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer